Pre-market hot trades in US stocks: Purple Biotech up 7.23% in pre-market; Abits up 7.17% in pre-market

Pre-market Hot Trades in US Stocks Purple Biotech is up 7.23% in pre-market trading. Based on recent key news: On April 17, Simcha Rock, a director of Purple Biotech, submitted Form 3, reporting ownership of 3,207,690 common shares and listing stock options covering 2,950,000 common shares with an exercise price of $0.06 or $0. This news may have boosted market confidence in the company's future development, driving the stock price up. Source: EDGAR system disclosed that the biotechnology industry has been active recently, with significant capital inflows. Abits is up 7.17% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Top Gainers in Pre-market US Stocks Psyence Biomedical is up 96.84% in pre-market trading. Based on recent key news: On April 17, Psyence Biomedical announced that its pharmaceutical-grade psychedelic drug NPX-5 is set for clinical trials. The company's CEO stated that this expansion marks an important step in advancing NPX-5's clinical infrastructure, supporting ongoing patient dosing. This news drove the stock price up by 69.85%. On April 18, U.S. President Trump signed an executive order to accelerate research and approval processes for psychedelic therapies, focusing on drugs like ibogaine. This move aims to assist veterans suffering from severe mental illnesses, further boosting the stock price. On April 19, Psyence Biomedical emphasized its fully integrated supply chain, capable of producing ibogaine at a commercial scale. This news sparked market discussions, driving the stock price up further. The acceleration of psychedelic drug research and clear policy support are evident. Theriva Biologics is up 77.26% in pre-market trading. Based on recent key news: On April 17, Theriva Biologics announced that it will present additional data from its VIRAGE 2B clinical trial at the AACR 2026 annual meeting. The trial involves the application of VCN-01 in metastatic pancreatic cancer, demonstrating improved overall survival and progression-free survival. This news drove the stock price up. Source: Reuters On April 17, the company plans to conduct a low-dose study to test whether more frequent and extended VCN-01 administration can further improve outcomes. This plan shows the company's confidence in its product, further boosting market sentiment. Source: GlobeNewswire On April 17, the clinical trial results from Theriva Biologics showed that patients using VCN-01 in combination with GnP performed better in overall survival and progression-free survival compared to those using GnP alone. This result enhanced investor confidence in the company's products, driving the stock price up Source: SEC Filing The biotechnology industry has recently shown active performance, with significant capital inflow. Clearmind Medicine pre-market rose 55.16%. Based on recent key news: On April 19, President Trump signed an executive order to accelerate the research and approval process for psychedelic therapies, focusing on substances like ibogaine for the treatment of post-traumatic stress disorder, depression, and addiction. This move aims to help veterans suffering from severe mental illnesses by providing them with new treatment options. This policy has driven a significant increase in Clearmind Medicine's stock price. On April 18, Trump announced reforms to expedite access to medical research and treatment based on psychedelic drugs. He plans to sign an executive order directing the U.S. Food and Drug Administration to accelerate the review of drugs like ibogaine. This news further stimulated market enthusiasm for investment in related pharmaceutical companies. The favorable policy for psychedelic therapies has led to a positive market response